Head-to-head · WeighScore
Breeze Meds vs Southern Vitality and Weight Loss
By GLP-1 ScorecardUpdated
Score comparison
Breeze Meds has the higher recorded score — 72.4/100 to 65.2/100.
Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Breeze Meds lists injection and dissolvable tablet options, but the public catalog does not establish what your next payment would be.
Before you choose
Before comparing the headline prices, the Breeze Meds review and the Southern Vitality and Weight Loss review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Breeze Meds vs Spry and Care Clinics vs Southern Vitality and Weight Loss compare each of them with another graded program, and the list of alternatives to Breeze Meds ranks the programs closest to Breeze Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the MyDrHank review covers one graded close to these two, at 68.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Breeze Meds | Southern Vitality and Weight Loss |
|---|---|---|
| WeighScore | 72.4/100 | 65.2/100 |
| Grade | C | C |
| Site position | #89 | #245 |
| Semaglutide | From $199/mo for injections; confirm selected price and supply | From $79 per 4 weeks on the 48-week prepaid plan ($948 up front) |
| Tirzepatide | Injections from $399 advertised; billing period not disclosed | From $120 per 4 weeks on the 48-week prepaid plan ($1,440 up front) |
| Coverage | FAQ advertises all 50 states | Georgia clinic; full telehealth coverage not confirmed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Not confirmed |
Strengths
- Publicly lists semaglutide injections from $199 per month
- Lists dissolvable tablet options for both medications
- The FAQ names Belmar and Strive as pharmacy partners
What to consider
- The listed tirzepatide starting price does not establish a billing period
- The FAQ question about costs displays a delivery answer
- Confirm the assigned pharmacy, what is included and any cancellation or refund terms
Strengths
- Names supervising physician Igor Ancor, MD and promises check-ins every two weeks
- Names its compounding pharmacy and publishes the 48-week prepaid totals
- One-time packages without automatic renewal; shipping included
What to consider
- The $79 per-four-week semaglutide headline requires $948 upfront for 48 weeks
- Shorter package prices are no longer on the public pages; four weeks is not a calendar month
- Orders become nonrefundable after approval and pharmacy submission; terms also finalize active orders after 30 days regardless of shipment
- Full program service-state list was not established; physician licensure claims alone do not settle eligibility
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.